Category Archives: Business of Biotech

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) invested in British Canadian Biosciences Corp., a privately held biotechnology company specializing in the development of peptides for the treatment of a variety of conditions, including cancer. Oncolytics has purchased all of the convertible preferred shares of BCBC in exchange for 200,000 common shares of Oncolytics. If converted to common shares, Oncolytics would own 10% of the outstanding BCBC common shares. In addition, Oncolytics has obtained a right, Read More >

Biotech Now’s Tracy Krughoff spoke with Dr. Tim Coetzee, president of Fast Forward, a subsidiary of the National Multiple Sclerosis Society. Fast Forward will be one of the advocacy organizations presenting at the Eighth Annual BIO Investor Forum. Listen now! http://www.bio.org/podcasts/coetzee.wma

Read a recent interview with Complete Genomics Chairman, President, and CEO Clifford Reid about his company’s top priorities, what makes his company attractive to investors, and what he hopes to accomplish at the 8th Annual BIO Investor Forum.  Complete Genomics sequenced its first genome in early 2009 and that data is publically available in the National Center for Biotechnology Information (NCBI) database. Already, in 2009, Complete Genomics has sequenced and delivered genomes to important collaborators Read More >

A year ago, CombinatoRx probably wouldn’t have guessed a multi-million dollar merger was on the horizon.  However, after crossing paths with Neuromed at the 2008 BIO Investor Forum, the company found itself en-route to a July 2009 announcement of a $30 million dollar merger.   The deal is expected to close this quarter. Read the full story at TheDeal.com.

Biotech-Now’s Tracy Krughoff spoke with Cure Duchenne’s President, Debra Miller. Cure Duchenne will be one of the patient advocacy organizations presenting at the Eighth Annual BIO Investor Forum next week. Listen Now!